Evidence-based treatment strategies in idiopathic pulmonary fibrosis

European Respiratory Review

Volumn 22, Issue 128, 2013, Pages 163-168

  Behr, Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cochrane; Evidence based; Guidelines; Idiopathic pulmonary fibrosis; Pirfenidone; Treatment recommendations

Indexed keywords

ACETYLCYSTEINE; ANTICOAGULANT AGENT; AZATHIOPRINE; CORTICOSTEROID; GAMMA1B INTERFERON; OXYGEN; PIRFENIDONE; PLACEBO; PREDNISONE;

ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FIBROSING ALVEOLITIS; HUMAN; LUNG TRANSPLANTATION; MONOTHERAPY; OXYGEN THERAPY; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE;

COCHRANE; EVIDENCE BASED; GUIDELINES; IDIOPATHIC PULMONARY FIBROSIS; PIRFENIDONE; TREATMENT RECOMMENDATIONS;

DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84878430262     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00001013     Document Type: Review

References (26)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American thoracic society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
2. Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
3. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 2006; 129: 174-181.
4. Schünemann HJ, Jaeschke R, Cook DJ, et al. Documents Development and Implementation Committee. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respr Crit Care Med 2006; 174: 605-614.
5. Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998; 157: 1063-1072.
6. Mulrow CD. Rationale for systematic reviews. BMJ 1994; 309: 597-599.
7. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-1482.
8. Noth I, Anstrom KJ, Calvert SB, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 88-95.
9. Behr J, Günther A, Ammenwerth W, et al. S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose. [German guideline for diagnosis and management of idiopathic pulmonary fibrosis.]. Pneumologie 2013; 67: 81-111.
10. Richeldi L, Davies HR, Ferrara G, et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003; 3: CD002880.
11. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242.
12. Hunninghake GW. Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2285-2287.
13. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-1977.
14. Behr J. Prednisone, azathioprine an N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 367: 869.
15. Davies HR, Richeldi L, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003; 3: CD003134.
16. Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010; 9: CD003134.
17. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon c-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-133.
18. King TE, Albera C, Bradford WZ, et al. Effect of interferon c-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-228.
19. Schaefer CJ, Ruhrmund DW, Pan L, et al. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011; 20: 85-97.
20. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respi Crit Care Med 2005; 171: 1040-1047.
21. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
22. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
23. Costabel U. Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients? Eur Respir Rev 2011; 20: 201-207.
24. European Medicines Agency. EPAR Esbriet. www.ema.europa.eu/ema/index.jsp?curl5pages/medicines/human/medicines/002154/human_med_001417.jsp&mid5WC0b01ac058001d124 Date last updated: January 14, 2013. Date last accessed: April 25, 2013.
25. Costabel U, Albera C, Cohen A, et al. The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Interim data from the RECAP extension study. Eur Respir J 2011; 38: Suppl. 55, 3S.
26. Cottin V. Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. Eur Respir Rev 2012; 21: 161-167.